Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Operations (2016 - 2025)

Cytosorbents' Cash from Operations history spans 15 years, with the latest figure at 4825000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 4825000.0 for Q4 2025, down 106.11% from a year ago — trailing twelve months through Dec 2025 was 12377000.0 (up 14.22% YoY), and the annual figure for FY2025 was 12377000.0, up 14.22%.
  • Cash from Operations for Q4 2025 was 4825000.0 at Cytosorbents, down from 2577000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1510045.0 in Q2 2025 to a low of 8119170.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 4809620.5 (2024), against an average of 4535000.85.
  • The sharpest move saw Cash from Operations crashed 419.15% in 2021, then surged 68.5% in 2025.
  • Year by year, Cash from Operations stood at 5491599.0 in 2021, then rose by 2.75% to 5340327.0 in 2022, then decreased by 19.98% to 6407411.0 in 2023, then skyrocketed by 63.46% to 2341000.0 in 2024, then plummeted by 106.11% to 4825000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 4825000.0, 2577000.0, and 1510045.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.